Vor Biopharma VOR
$ 0.86
-2.67%
Quarterly report 2024-Q3
added 11-07-2024
Vor Biopharma Balance Sheet 2011-2024 | VOR
Annual Balance Sheet Vor Biopharma
2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
4.3 M | -18.8 M | -102 M | -30.2 M | -6.47 M | 3.53 M | - | - | - | - | - | - | - |
Long Term Debt |
31.8 M | 35.6 M | 16.2 M | - | - | - | - | - | - | - | - | - | - |
Long Term Debt Current |
3.83 M | 3.27 M | 1.84 M | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | 17.4 M | 25.1 M | 2 K | - | - | - | - | - | - | - |
Total Current Liabilities |
15.6 M | 13.1 M | 10.2 M | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
47.4 M | 48.8 M | 26.3 M | 27.6 M | 27.3 M | 7.78 M | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-340 M | -222 M | -130 M | -61.2 M | -17.9 M | -7.05 M | - | - | - | - | - | - | - |
Total Assets |
198 M | 299 M | 243 M | 75.9 M | 9.83 M | 1.01 M | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
31.4 M | 57.7 M | 120 M | - | - | - | - | - | - | - | - | - | - |
Book Value |
151 M | 251 M | 216 M | 48.3 M | -17.4 M | -6.77 M | - | - | - | - | - | - | - |
Total Shareholders Equity |
151 M | 251 M | 216 M | -59.1 M | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Balance Sheet Vor Biopharma
2024-Q3 | 2024-Q2 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
28.7 M | 29.7 M | 31.8 M | 32.9 M | 33.8 M | 34.7 M | 35.6 M | 36.5 M | 37.4 M | 21.7 M | 16.2 M | 16.5 M | 16.7 M | 17.1 M | 17.4 M | 17.4 M | 17.4 M | 17.4 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
43 M | 43.5 M | 47.4 M | 48.2 M | 46.5 M | 47.3 M | 48.8 M | 47.6 M | 49.6 M | 39.8 M | 26.3 M | 25.7 M | 25 M | 25.8 M | 27.6 M | 27.6 M | 27.6 M | 27.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-426 M | -399 M | -340 M | -314 M | -281 M | -251 M | -222 M | -198 M | -175 M | -153 M | -130 M | -112 M | -93.3 M | -74.9 M | -61.2 M | -61.2 M | -61.2 M | -61.2 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
116 M | 142 M | 198 M | 223 M | 251 M | 278 M | 299 M | 206 M | 225 M | 234 M | 243 M | 259 M | 275 M | 293 M | 75.9 M | 75.9 M | 75.9 M | 75.9 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
52.8 M | 76.1 M | 31.4 M | 45 M | 32.2 M | 42.5 M | 57.7 M | 60.8 M | 63 M | 90 M | 120 M | 143 M | 170 M | 263 M | 48.5 M | 48.5 M | 48.5 M | 48.5 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
73 M | 98.1 M | 151 M | 175 M | 204 M | 230 M | 251 M | 159 M | 175 M | 194 M | 216 M | 233 M | 250 M | 267 M | 48.3 M | 48.3 M | 48.3 M | 48.3 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
73 M | 98.1 M | 151 M | 175 M | 204 M | 230 M | 251 M | 159 M | 175 M | 194 M | 216 M | 233 M | 250 M | 267 M | -59.1 M | -59.1 M | -59.1 M | -59.1 M | -17.4 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency